NDRAENDRA Life Sciences Inc.
- BusinessWire
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial ...
- GlobeNewswire
ASP Isotopes Issues Letter to Shareholders
DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes", "ASPI" or the "Company"), an advanced materials company focused on developing technologies and ...
- AccessWire
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Noble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNGLearn why the Virginia Gas Project is positioned to become one of the world's ...
- PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--FSRL, SYNA, TECH, and NDRA
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for... ...
- BusinessWire
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen’s Virginia Gas Project Listing expected to provide investors with direct exposure to one of the few publicly ...
- GlobeNewswire
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen’s Virginia Gas Project Listing expected to provide investors with direct exposure to one of the few publicly ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences with a Buy and lowers the price target from $27 to $25. ...
- BusinessWire
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for ...
- BusinessWire
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
Results confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ENDRA Life Sciences Inc. (NASDAQ:NDRA) ...
- BusinessWire
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for ...
- BusinessWire
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
Board to evaluate a range of alternatives while continuing to support core business priorities ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early ...
- BusinessWire
ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences with a Buy and lowers the price target from $38 to $30. ...
- BusinessWire
ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc. (NASDAQ:NDRA) ...
- BusinessWire
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
TAEUS Liver demonstrates strong agreement with the industry's imaging gold standard, MRI‑PDFF, across the full spectrum of steatotic liver disease and patient BMI ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the ...
- BusinessWire
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease ("MASLD") and ...
- BusinessWire
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
ENDRA is converting static treasury assets into a dynamic rewards engine to support medical innovation ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in imaging technologies for the early ...
- BusinessWire
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings
Company Officially Launches Digital Asset Treasury Strategy Focused on the Highest Conviction Holdings of Arca Investment Management to Enhance Long-Term Shareholder Value ENDRA Life Sciences Inc. (NASDAQ:NDRA) ...
- SEC
PRE 14A Form - Other preliminary proxy statements - ENDRA Life Sciences Inc. (0001681682) (Filer)
Other preliminary proxy statements ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - ENDRA Life Sciences Inc. (0001681682) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
8-K/A Form - [Amend] Current report, items 1.01, 1.02, 3.02, 5.08, 7.01, 8.01, and 9.01 - ENDRA Life Sciences Inc. (0001681682) (Filer)
[Amend] Current report, items 1.01, 1.02, 3.02, 5.08, 7.01, 8.01, and 9.01 ...
- SEC
8-K Form - Current report, item 9.01 - ENDRA Life Sciences Inc. (0001681682) (Filer)
Current report, item 9.01 ...
- BusinessWire
ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca
Company Also Intends to Appoint Jeff Dorman to Digital Asset Advisory Board ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in imaging technologies for the early detection and monitoring ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences with a Buy and lowers the price target from $46 to $38. ...
- BusinessWire
ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results
ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, ...